Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

TY - JOUR

T1 - Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

AU - Brüggemann, M

AU - Schrauder, A

AU - Raff, T

AU - Pfeifer, H

AU - Dworzak, M

AU - Ottmann, O G

AU - Asnafi, V

AU - Baruchel, A

AU - Bassan, R

AU - Benoit, Y

AU - Biondi, A

AU - Cavé, H

AU - Dombret, H

AU - Fielding, A K

AU - Foà, R

AU - Gökbuget, N

AU - Goldstone, A H

AU - Goulden, N

AU - Henze, G

AU - Hoelzer, D

AU - Janka-Schaub, G E

AU - Macintyre, E A

AU - Pieters, R

AU - Rambaldi, A

AU - Ribera, J-M

AU - Schmiegelow, K

AU - Spinelli, O

AU - Stary, J

AU - von Stackelberg, A

AU - Kneba, M

AU - Schrappe, M

AU - van Dongen, J J M

AU - European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

AB - Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

U2 - 10.1038/leu.2009.268

DO - 10.1038/leu.2009.268

M3 - Journal article

SN - 0887-6924

VL - 24

SP - 521

EP - 535

JO - Leukemia

JF - Leukemia

IS - 3

ER -